William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer
Lynn Sage Breast Cancer Symposium 2024
William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology; Professor, Medicine (Hematology and Oncology), at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago.
Presented at the Lynn Sage Breast Cancer Symposium, hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago. Filmed November 1, 2024.
Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Badve is Professor, Department of Pathology and Laboratory Medicine, and Vice Chair, Pathology Cancer Programs, at Emory University School of Medicine in Atlanta. Presented at the Lynn Sage Breast Cancer Symposium, hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago. Filmed October 31, 2024.
The ASCO Post Staff
Charles E. Geyer, Jr, MD, FACP, discusses the management of patients with HER2-positive breast cancer in 2024, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Geyer is Professor of Medicine and Interim Division Chief of Malignant Hematology and Medical Oncology at the University of Pittsburgh Medical Center (UPMC/Hillman Cancer Center; Dr. Geyer is also Chief Scientific Officer, National Surgical Adiuvant Breast and Bowel Project (NSABP) Foundation. Presented at the Lynn Sage Breast Cancer Symposium, hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago. Filmed October 25, 2024.
The ASCO Post Staff
Frederick Howard, MD, discusses the role of targeted therapy and endocrine therapy in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Howard is Assistant Professor of Medicine in the section of Hematology/Oncology at the University of Chicago. Presented at the Lynn Sage Breast Cancer Symposium, hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.
